ECP 2018 Final Programme

Tuesday, 11 Sept 175 ECP 2018 · Bilbao Breakfast and Luncheon Industry Symposia e Tuesday, 11 September 2018 BRM-02 Industry Symposium 07:15 – 08:15 Barria TRK fusion cancer testing and its importance in precision oncology (Bayer) Chair: Frédérique Penault-Llorca, France 001 07:15 – 07:20 Welcome and introduction Frédérique Penault-Llorca, France 002 07:20 – 07:40 The role of TRK fusions in oncogenesis Frédérique Penault-Llorca, France 003 07:40 – 08:00 TRK fusion cancer testing Albrecht Stenzinger, Germany 004 08:00 – 08:15 Q&A All faculty BRM-03 Industry Symposium 07:15 – 08:15 Room A2 The launch of the fully automated Idylla TM MSI Test: A new era in molecular MSI Testing (Biocartis) Chair: Caroline Jans, Belgium 001 A new era in MSI testing –Discovery, benefits and clinical performance of Idylla™MSI Bram De Craene, Belgium 002 Clinical evidence on Idylla™MSI in colorectal cancer; a multi-center evaluation Elena Guerini Rocco, Italy 003 The Idylla™MSI: A laboratory user perspective Sofie Metsu, Belgium LS-09 Industry Symposium 13:00 – 14:30 Room A1 Precision Medicine Starts with Pathology: Immuno-Oncology Biomarkers and Your Practice (BMS) Chair: Reinhard Büttner, Germany 001 13:00 – 13:05 Welcome and introductions Reinhard Büttner, Germany 002 13:05 – 13:10 The need for precision medicine through biomarkers in Immuno-Oncology (I-O) Nicola Normanno, Italy 003 13:10 – 13:25 Programmed death ligand 1 (PD-L1): The first wave in I-O biomarkers Reinhard Büttner, Germany 004 13:25 – 13:45 Exploring the next wave in I-O biomarkers: Tumour mutational burden (TMB) Nicola Normanno, Italy 005 13:45 – 14:05 Testing for TMB and other genomic biomarkers Frédérique Penault-Llorca, France 006 14:05 – 14:15 What is on the horizon? Reinhard Büttner, Germany 007 14:15 – 14:25 Q&A session Full faculty 008 14:25 – 14:30 Closing remarks Reinhard Büttner, Germany